Treatment of Comorbid Anxiety and Depression

Introduction to Sertraline

• The American College of Cardiology is not relevant here, however, sertraline is specifically recommended as the first-line SSRI for patients with both depression and anxiety due to its optimal balance of efficacy, safety, and tolerability 1
• Sertraline is FDA-approved for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD—making it ideal for this patient's anxiety-predominant presentation 1

Why Bupropion is Problematic

• Bupropion is inherently activating and commonly causes anxiety and nausea as side effects, making it particularly problematic for patients with prominent anxiety symptoms 2
• The FDA label explicitly warns that bupropion should not be used in agitated patients, and this patient's increased anxiety represents treatment-emergent agitation 2

Practical Implementation Strategy

• Start sertraline 50 mg daily in the morning, as a favorable starting dose for patients with anxiety and depression 1
• Increase sertraline in 50 mg increments at 1-2 week intervals if response is inadequate, up to a maximum of 200 mg daily 1
• Allow 6-8 weeks for an adequate trial, including at least 2 weeks at the maximum tolerated dose 1

Critical Monitoring Parameters

• Monitor for treatment-emergent suicidality closely during the first 1-2 weeks after initiation or dose changes, as all SSRIs carry FDA black box warnings for suicidal thinking in young adults 1
• Assess treatment response at 4 weeks and 8 weeks using standardized symptom rating scales 1

Addressing the ADHD Component

• Once anxiety and depression are stabilized on sertraline, reassess ADHD symptoms to determine if stimulant medication is needed 3
• Stimulants can be safely combined with SSRIs, as there are no significant drug-drug interactions between sertraline and stimulants like methylphenidate or amphetamines 3

Common Pitfalls to Avoid

• Do not continue bupropion hoping the anxiety will resolve—the activating properties are intrinsic to the medication and unlikely to improve with time in an already anxious patient 2
• Do not switch to paroxetine despite its FDA approval for multiple anxiety disorders, as it has significantly higher risk of discontinuation syndrome and increased suicidal thinking compared to sertraline 1

If Sertraline Fails After Adequate Trial

• Switch to venlafaxine extended-release 75-225 mg daily, which demonstrated statistically significantly better response rates than fluoxetine specifically for depression with prominent anxiety symptoms 1
• Consider adding cognitive behavioral therapy (CBT), as combination treatment (CBT + SSRI) is superior to either alone for anxiety disorders 1